Chronic lymphocytic leukemia B-cell-derived TNFα impairs bone marrow myelopoiesis

Bryce A. Manso; Jordan E. Krull; Kimberly A. Gwin; Petra K. Lothert; Baustin M. Welch; Anne J. Novak; Sameer A. Parikh; Neil E. Kay; Kay L. Medina

doi:10.1016/j.isci.2020.101994

Chronic lymphocytic leukemia B-cell-derived TNFα impairs bone marrow myelopoiesis

Bryce A. Manso, Jordan E. Krull, Kimberly A. Gwin, Petra K. Lothert, Baustin M. Welch, Anne J. Novak, Sameer A. Parikh, Neil E. Kay, Kay L. Medina

Research output: Contribution to journal › Article › peer-review

Abstract

TNFα is implicated in chronic lymphocytic leukemia (CLL) immunosuppression and disease progression. TNFα is constitutively produced by CLL B cells and is a negative regulator of bone marrow (BM) myelopoiesis. Here, we show that co-culture of CLL B cells with purified normal human hematopoietic stem and progenitor cells (HSPCs) directly altered protein levels of the myeloid and erythroid cell fate determinants PU.1 and GATA-2 at the single-cell level within transitional HSPC subsets, mimicking ex vivo expression patterns. Physical separation of CLL cells from control HSPCs or neutralizing TNFα abrogated upregulation of PU.1, yet restoration of GATA-2 required TNFα neutralization, suggesting both cell contact and soluble-factor-mediated regulation. We further show that CLL patient BM myeloid progenitors are diminished in frequency and function, an effect recapitulated by chronic exposure of control HSPCs to low-dose TNFα. These findings implicate CLL B-cell-derived TNFα in impaired BM myelopoiesis.

Original language	English (US)
Article number	101994
Journal	iScience
Volume	24
Issue number	1
DOIs	https://doi.org/10.1016/j.isci.2020.101994
State	Published - Jan 22 2021

Keywords

Immunology
Molecular Biology
Stem Cells Research

ASJC Scopus subject areas

General

Access to Document

10.1016/j.isci.2020.101994

Fingerprint Dive into the research topics of 'Chronic lymphocytic leukemia B-cell-derived TNFα impairs bone marrow myelopoiesis'. Together they form a unique fingerprint.

Cite this

@article{3a255261d0634391aed1cdfba36c3739,

title = "Chronic lymphocytic leukemia B-cell-derived TNFα impairs bone marrow myelopoiesis",

abstract = "TNFα is implicated in chronic lymphocytic leukemia (CLL) immunosuppression and disease progression. TNFα is constitutively produced by CLL B cells and is a negative regulator of bone marrow (BM) myelopoiesis. Here, we show that co-culture of CLL B cells with purified normal human hematopoietic stem and progenitor cells (HSPCs) directly altered protein levels of the myeloid and erythroid cell fate determinants PU.1 and GATA-2 at the single-cell level within transitional HSPC subsets, mimicking ex vivo expression patterns. Physical separation of CLL cells from control HSPCs or neutralizing TNFα abrogated upregulation of PU.1, yet restoration of GATA-2 required TNFα neutralization, suggesting both cell contact and soluble-factor-mediated regulation. We further show that CLL patient BM myeloid progenitors are diminished in frequency and function, an effect recapitulated by chronic exposure of control HSPCs to low-dose TNFα. These findings implicate CLL B-cell-derived TNFα in impaired BM myelopoiesis.",

keywords = "Immunology, Molecular Biology, Stem Cells Research",

author = "Manso, {Bryce A.} and Krull, {Jordan E.} and Gwin, {Kimberly A.} and Lothert, {Petra K.} and Welch, {Baustin M.} and Novak, {Anne J.} and Parikh, {Sameer A.} and Kay, {Neil E.} and Medina, {Kay L.}",

note = "Funding Information: We thank Dr. Susan Slager for statistical advice and Susan Schwager for providing CLL patient data. The Mayo Clinic Department of Hematology specimen processing and the Predolin biobanking team provided many of the samples utilized in this study. We also thank Matthew Holets and the Mayo Clinic Charlton Clinical Research and Trials Unit for assisting with donor recruitment and sample collection. This study was supported by Mayo Clinic NIH Grant Relief funding to K.L.M. and NIH T32 funding ( NIH T32 AI07425-23 ) awarded to B.A.M. ",

year = "2021",

month = jan,

day = "22",

doi = "10.1016/j.isci.2020.101994",

language = "English (US)",

volume = "24",

journal = "iScience",

issn = "2589-0042",

publisher = "Elsevier Inc.",

number = "1",

}

TY - JOUR

T1 - Chronic lymphocytic leukemia B-cell-derived TNFα impairs bone marrow myelopoiesis

AU - Manso, Bryce A.

AU - Krull, Jordan E.

AU - Gwin, Kimberly A.

AU - Lothert, Petra K.

AU - Welch, Baustin M.

AU - Novak, Anne J.

AU - Parikh, Sameer A.

AU - Kay, Neil E.

AU - Medina, Kay L.

N1 - Funding Information: We thank Dr. Susan Slager for statistical advice and Susan Schwager for providing CLL patient data. The Mayo Clinic Department of Hematology specimen processing and the Predolin biobanking team provided many of the samples utilized in this study. We also thank Matthew Holets and the Mayo Clinic Charlton Clinical Research and Trials Unit for assisting with donor recruitment and sample collection. This study was supported by Mayo Clinic NIH Grant Relief funding to K.L.M. and NIH T32 funding ( NIH T32 AI07425-23 ) awarded to B.A.M.

PY - 2021/1/22

Y1 - 2021/1/22

N2 - TNFα is implicated in chronic lymphocytic leukemia (CLL) immunosuppression and disease progression. TNFα is constitutively produced by CLL B cells and is a negative regulator of bone marrow (BM) myelopoiesis. Here, we show that co-culture of CLL B cells with purified normal human hematopoietic stem and progenitor cells (HSPCs) directly altered protein levels of the myeloid and erythroid cell fate determinants PU.1 and GATA-2 at the single-cell level within transitional HSPC subsets, mimicking ex vivo expression patterns. Physical separation of CLL cells from control HSPCs or neutralizing TNFα abrogated upregulation of PU.1, yet restoration of GATA-2 required TNFα neutralization, suggesting both cell contact and soluble-factor-mediated regulation. We further show that CLL patient BM myeloid progenitors are diminished in frequency and function, an effect recapitulated by chronic exposure of control HSPCs to low-dose TNFα. These findings implicate CLL B-cell-derived TNFα in impaired BM myelopoiesis.

AB - TNFα is implicated in chronic lymphocytic leukemia (CLL) immunosuppression and disease progression. TNFα is constitutively produced by CLL B cells and is a negative regulator of bone marrow (BM) myelopoiesis. Here, we show that co-culture of CLL B cells with purified normal human hematopoietic stem and progenitor cells (HSPCs) directly altered protein levels of the myeloid and erythroid cell fate determinants PU.1 and GATA-2 at the single-cell level within transitional HSPC subsets, mimicking ex vivo expression patterns. Physical separation of CLL cells from control HSPCs or neutralizing TNFα abrogated upregulation of PU.1, yet restoration of GATA-2 required TNFα neutralization, suggesting both cell contact and soluble-factor-mediated regulation. We further show that CLL patient BM myeloid progenitors are diminished in frequency and function, an effect recapitulated by chronic exposure of control HSPCs to low-dose TNFα. These findings implicate CLL B-cell-derived TNFα in impaired BM myelopoiesis.

KW - Immunology

KW - Molecular Biology

KW - Stem Cells Research

UR - http://www.scopus.com/inward/record.url?scp=85098800476&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85098800476&partnerID=8YFLogxK

U2 - 10.1016/j.isci.2020.101994

DO - 10.1016/j.isci.2020.101994

M3 - Article

AN - SCOPUS:85098800476

VL - 24

JO - iScience

JF - iScience

SN - 2589-0042

IS - 1

M1 - 101994

ER -